Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Massachusetts General Hospital
With
ElMindA Ltd
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
For Patients with Major Depressive Disorder
• Male and female outpatients, aged 18-55 years
* Subjects meeting full criteria for the diagnosis of current Major Depressive Disorder (MDD) without psychotic features, as determined by clinical evaluation and Mood Module of structured diagnostic interview (SCID), completed by the study clinician.
* HAM-D17 score of 14 or higher
* Able to provide informed consent
* Right handed, normal (corrected) vision and normal hearing
Males and females, aged 18-55 years
Subjects who do not meet full criteria for any of the major psychiatric diagnosis including MDD, bipolar disorder, schizophrenia, substance abuse/dependence, attention deficit hyperactivity disorder (ADHD), as determined by clinical evaluation and structured diagnostic interview, completed by the study clinician.
Right handed, normal (corrected) vision and normal hearing
You may not be if
• Other primary diagnoses including major depressive disorder with psychotic features, bipolar disorder, schizoaffective disorder, schizophrenia, dementia, attention deficit hyperactivity disorder (ADHD).
* Substance use disorder (abuse or dependence with active use within the last 6 months).
* Significant sensory deficits such as deafness or blindness.
* Severe or unstable medical illness, including history of closed head injury resulting in loss of consciousness, seizure disorder; history of neurological disorders.
* Pregnant or nursing females who are not using an accepted method of contraception (birth control pill, IUD, combination of barrier methods)
* Clinically significant abnormal laboratory values or electrocardiogram For Healthy Controls
Any current primary psychiatric, or medical condition determined to be clinically significant.
Current use of psychotropics or any medication with clinically significant central nervous system effects.
